Genomic instability is a major problem in cancer progression and therapy resistance. Cytura Therapeutics aims to find a solution to stop destabilization of the genome.
By targeting genomic instability both as a stand-alone therapy, as well as in combination therapy, therapy resistance or relapse can be avoided.
This will help make cancer treatment more effective and improve the lives of patients worldwide.
Cambrex is a leading global supplier of more than 100 generic APIs.
With over 35 years experience and a growing team of over 2,000 experts servicing our global clients from our sites in North America and Europe,
we are tried and trusted in branded and generic markets for API and dosage form development and manufacturing.
Cambrex can support your project in regulated, emerging and developing markets. We are in your neighborhood, wherever you are.